Beiträge
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2023-10-19 / Methods Cell Biol 2024;183:51-113Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen /von 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228The Application of Evidence-Based Medicine in Individualized Medicine
/in International Publications, IOZK Veröffentlichungen /von 2023-06-23 / Biomedicines 2023 Jun;11(7)Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK Veröffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
/in International Publications, IOZK Veröffentlichungen /von 2020-11-22 / Biomedicines 2020 Nov;8(11)Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in International Publications, IOZK Veröffentlichungen /von 2020-07-23 / Biomedicines 2020 Jul;8(8)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de